Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votesGovInfo API
Floor speeches, reports, bill textFederal Election Commission (FEC)
Campaign financeVoteView (UCLA)
Ideology scores (DW-NOMINATE)GovTrack.us
Misconduct data (CC0)U.S. Census Bureau
District demographics
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

S3797Referred to Committee

Prohibiting Tianeptine and Other Dangerous Products Act of 2026

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-02-05
Introduced
1
Cosponsors
S
ⓘ
Type

Sponsor

Richard J. Durbin
Richard J. Durbin
Democrat · IL · Senator
Votes with party: 56.8% (322 recorded votes)

Full profile: /officials/D000563

Source: Congress.gov · FEC

Cosponsors (1)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Richard Blumenthal (D-CT)Original· 2026-02-05

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S512)

2026-02-05

Source: Congress.gov

Plain-English Summary

This bill would ban the sale and distribution of tianeptine, a drug sometimes sold as a dietary supplement or nootropic that can cause addiction and serious health problems, along with other potentially dangerous products. The ban would apply to retailers, online sellers, and manufacturers who currently market these substances to consumers. The legislation aims to protect public health by preventing access to drugs that lack proper FDA approval and oversight.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • SRES748A resolution condemning the Department of Justice and Internal Revenue Service settlement agreement in Trump v. Internal Revenue Service, under which $1,776,000,000 in taxpayer money may be used to financially benefit individuals who assaulted law enforcement officers on January 6, 2021, and President Trump, his family, and his political allies.
    Referred to Committee · 2026-05-21
  • S4608A bill to prohibit the imposition of the death penalty for any violation of Federal law, and for other purposes.
    Referred to Committee · 2026-05-20
  • S4566Increasing Access to Lung Cancer Screening Act
    Referred to Committee · 2026-05-19
  • S4541Senator Paul Simon Study Abroad Program Act of 2026
    Referred to Committee · 2026-05-14